Pfizer's Exubera Flop

Needle-free insulin was supposed to be the next big thing in drugs. Turns out patients aren't interestedit'll cost Pfizer $2.8 billion

Exubera was supposed to revolutionize diabetes care. It was the first inhalable insulin product on the market, invented by biotech startup Nektar Therapeutics (NKTR) and shepherded to market by drug giant Pfizer (PFE), which predicted it would eventually bring in $2 billion a year in sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.